In the Mix: 1 More Article — May 25, 2026
InMed Pharmaceuticals Q3 2025 earnings reveal continued financial losses impacting cannabinoid therapeutics development. This highlights challenges in pharmaceutical cannabinoid products. Clinicians should note the ongoing difficulties in drug…
7 on 7: The biggest stories from last week you might’ve missed
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchMedical MarijuanaSchedulingHealthcareRegulationFederal Why This Matters # Clinical RelevanceThe…
A 44-year study has found that long-term cannabis use does NOT accelerate cognitive … – Facebook
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. NeurologyResearchAgingTHCSafetyMental HealthCannabis Clinical Summary A longitudinal study spanning 44 years…
UK’s Care Quality Commission Raises Concerns Following Alternaleaf Inspection
The UK Care Quality Commission cannabis inspection identified regulatory concerns relevant to clinicians referring patients to licensed producers. These findings emphasize the importance of quality and safety in medical cannabis prescribing. Clinicians…
TGA officials to join cannabis prescribers for annual ANZCCP conference – Cannabiz
✦ New CED Clinical Relevance #61 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchIndustrySafetyClinical PracticeRegulationProfessional Development Why This Matters # Clinical…
Marijuana tied to weight loss in new Fed study | Cannabis Sciences – Labroots
✦ New CED Clinical Relevance #68 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchTHCSafetyCannabis SciencesObesityHealth OutcomesMetabolism Clinical Summary A recent study published in The…
LEVEL Sleep Protab Improved Sleep Quality and Next-Morning Outcomes in Independent …
✦ New CED Clinical Relevance #76 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. SleepResearchCBDTHCSafetyDosingIndustry Clinical Summary # Clinical Summary A 29-day independent study evaluated…
Cannabis Rescheduling Arrives, With Limits: What The DOJ’s Final Order Does And Doesn’t Do
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PolicyResearchTHCCBDHempIndustrySafety Why This Matters Cannabis rescheduling to Schedule III will enable clinical…
SYT-510 for Generalized Anxiety Disorder: Phase 2 Trial Dosing Initiated | Psychiatric Times
✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. AnxietyMental HealthResearchDosingSafetyNeurologyIndustry Why This Matters Clinicians treating generalized anxiety…
Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder
✦ New CED Clinical Relevance #75 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. AnxietyMental HealthNeurologyResearchSafetyIndustrySleep Why This Matters Clinicians treating generalized anxiety…